Urine test to detect clinically important prostate cancer
Project 2 - Validation and clinical utility of a multiplex urine biomarker for identification of clinically significant prostate cancer
This project uses a urine test called MPS2 to help men with elevated PSA or under active surveillance find clinically important prostate cancers (Grade Group ≥2).
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11196276 on NIH RePORTER |
What this research studies
You would give a urine sample that is tested with a new biomarker called MPS2. Men with elevated PSA who are deciding about biopsy are randomly assigned to have decisions guided by MPS2 versus the usual MRI-based approach at University of Michigan and Karmanos Cancer Institute. The trial will compare how well MPS2 finds important cancers while trying to reduce unnecessary MRIs and biopsies. Researchers will also analyze urine samples from men on active surveillance to see if MPS2 can detect cancers becoming more aggressive.
Who could benefit from this research
Good fit: Ideal candidates are men with an elevated PSA considering a prostate biopsy and men on active surveillance for low-risk prostate cancer.
Not a fit: Men who already have high-risk or advanced prostate cancer, or men without elevated PSA or prostate concerns, are unlikely to benefit from this diagnostic test.
Why it matters
Potential benefit: If successful, this could spare many men from unnecessary MRIs and biopsies while still finding cancers that need treatment.
How similar studies have performed: Earlier urine-based tests, including the original MyProstateScore, have shown promising results, but randomized comparisons with MRI-based approaches are still limited.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Morgan, Todd M. — University of Michigan at Ann Arbor
- Study coordinator: Morgan, Todd M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.